Formulation Development for Transdermal Delivery of Raloxifene, a Chemoprophylactic Agent against Breast Cancer

• Main Authors: Deepal Vora (Author), Amruta Dandekar (Author), Sonalika Bhattaccharjee (Author), Onkar N. Singh (Author), Vivek Agrahari (Author), M. Melissa Peet (Author), Gustavo F. Doncel (Author), Ajay K. Banga (Author)
• Format: Book
• Published: MDPI AG, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Raloxifene (RLX) is a second-generation selective estrogen receptor modulator approved for the prevention of invasive breast cancer in women. Oral therapy of RLX requires daily intake and is associated with side effects that may lead to low adherence. We developed a weekly transdermal delivery syste...